A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer
The objectives of this study are to assess the safety, pharmacokinetics, immunogenicity and
anti-tumour activity of AGS15E in subjects with metastatic urothelial cancer who failed at
least one prior chemotherapy regimen for metastatic disease.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society